Cargando…

Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?

Despite the availability of a lot of effective disease-modifying drugs, multiple sclerosis (MS) (in particular the progressive forms) still represents an important unmet medical need, because of issues in terms of effectiveness, duration of response, safety, and patient compliance. An increasing bod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brancati, Serena, Gozzo, Lucia, Longo, Laura, Vitale, Daniela Cristina, Drago, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290177/ https://www.ncbi.nlm.nih.gov/pubmed/34295328 http://dx.doi.org/10.3389/fimmu.2021.661882

Ejemplares similares

The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries
por: Gozzo, Lucia, et al.
Publicado: (2023)

Fertility Preservation in Female Pediatric Patients With Cancer: A Clinical and Regulatory Issue
por: Brancati, Serena, et al.
Publicado: (2021)

The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience
por: Gozzo, Lucia, et al.
Publicado: (2020)

Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap
por: Gozzo, Lucia, et al.
Publicado: (2020)

Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries
por: Gozzo, Lucia, et al.
Publicado: (2021)

Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries
por: Gozzo, Lucia, et al.
Publicado: (2022)

The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review
por: Gozzo, Lucia, et al.
Publicado: (2020)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?
por: Macdonald, Judith C., et al.
Publicado: (2021)

Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database
por: Gozzo, Lucia, et al.
Publicado: (2021)

Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data
por: Gozzo, Lucia, et al.
Publicado: (2023)

Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption
por: Gröning, Remigius, et al.
Publicado: (2023)

Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis
por: Iannello, Andrea, et al.
Publicado: (2019)

Bioequivalence, Drugs with Narrow Therapeutic Index and the Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution
por: Gozzo, Lucia, et al.
Publicado: (2022)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Lymphoid Aggregates in the CNS of Progressive Multiple Sclerosis Patients Lack Regulatory T Cells
por: Bell, Luisa, et al.
Publicado: (2020)

Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis
por: Jamois, Candice, et al.
Publicado: (2022)

Regulatory T Cells in Systemic Sclerosis
por: Frantz, Camelia, et al.
Publicado: (2018)

Editorial: Innovative treatments for neuro-psychiatric diseases
por: Gozzo, Lucia, et al.
Publicado: (2023)

Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis
por: Kashani, Nicole, et al.
Publicado: (2021)

Mesenchymal Stem Cells: Are We Ready for Clinical Application in Transplantation and Tissue Regeneration?
por: Hoogduijn, Martin J., et al.
Publicado: (2013)

Regulatory Approved Monoclonal Antibodies Contain Framework Mutations Predicted From Human Antibody Repertoires
por: Petersen, Brian M., et al.
Publicado: (2021)

Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis
por: Pozzato, Mattia, et al.
Publicado: (2021)

Low Memory T Cells Blood Counts and High Naïve Regulatory T Cells Percentage at Relapsing Remitting Multiple Sclerosis Diagnosis
por: Canto-Gomes, João, et al.
Publicado: (2022)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis
por: Li, Ruoyu, et al.
Publicado: (2022)

Rituximab for the treatment of multiple sclerosis: a review
por: Chisari, Clara Grazia, et al.
Publicado: (2021)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis
por: Gaetani, Lorenzo, et al.
Publicado: (2020)

Advances in understanding gray matter pathology in multiple sclerosis: Are we ready to redefine disease pathogenesis?
por: Zivadinov, Robert, et al.
Publicado: (2012)

Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients—High Efficacy of Rituximab
por: Gernert, Michael, et al.
Publicado: (2022)

CCR6 blockade on regulatory T cells ameliorates experimental model of multiple sclerosis
por: JATCZAK-PAWLIK, IZABELA, et al.
Publicado: (2020)

Rituximab as Rescue Therapy for Aggressive Pediatric Multiple Sclerosis
por: Vartzelis, George, et al.
Publicado: (2019)

Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab
por: Perriguey, Marine, et al.
Publicado: (2021)

Rituximab resistance in ITP and beyond
por: Xiao, Zhengrui, et al.
Publicado: (2023)

Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
por: Severa, Martina, et al.
Publicado: (2020)

The Role of Astrocytes in Multiple Sclerosis
por: Ponath, Gerald, et al.
Publicado: (2018)

The Cerebrospinal Fluid in Multiple Sclerosis
por: Deisenhammer, Florian, et al.
Publicado: (2019)

Digital Twins for Multiple Sclerosis
por: Voigt, Isabel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vqg5dshclm2rfa3bbs5v86nudd